Elvan Cavaç, Ph.D.
About Elvan Cavaç, Ph.D.
Elvan Cavaç, Ph.D., is a Scientist II specializing in mRNA upstream process development at Tessera Therapeutics. He holds a Ph.D. in Chemistry and an MBA from the University of Massachusetts Amherst, where he also completed various research and innovation roles.
Work at Tessera Therapeutics
Elvan Cavaç, Ph.D., serves as Scientist II in mRNA Upstream Process Development at Tessera Therapeutics. He has been with the company since 2021, contributing to advancements in mRNA technology. His role focuses on optimizing upstream processes, which are critical for the production of mRNA therapeutics. This position allows him to apply his extensive background in chemistry and drug development to innovate within the field.
Education and Expertise
Elvan Cavaç holds a Doctor of Philosophy (Ph.D.) in Chemistry from the University of Massachusetts Amherst, where he studied from 2014 to 2020. He also earned a Master of Business Administration (MBA) from the same institution, completing his studies from 2020 to 2022. Additionally, he has a Bachelor of Arts (B.A.) in Chemistry and Theater from St. Olaf College, obtained from 2009 to 2013. This diverse educational background equips him with a unique blend of scientific and business acumen.
Background
Elvan Cavaç has a significant academic and professional background in chemistry and drug development. He began his research career as a Graduate Research Fellow at the University of Massachusetts Amherst, where he worked from 2014 to 2020. Following this, he held various positions, including a Business Innovation Fellow at the UMass Institute for Applied Life Sciences and a role in Drug Development Strategy at Roivant Sciences. His experiences have shaped his expertise in the life sciences sector.
Professional Experience
Throughout his career, Elvan Cavaç has held multiple positions that highlight his expertise in the life sciences. He worked at the University of Massachusetts Amherst's Center for International Securities and Derivatives Markets for four months in 2021. His brief tenure at Roivant Sciences in Drug Development Strategy further demonstrates his involvement in strategic roles within the pharmaceutical industry. These experiences contribute to his current work at Tessera Therapeutics.